Copyright Reports & Markets. All rights reserved.

Global Reritinib Mesylate Tablets Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Reritinib Mesylate Tablets Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 100mg / tablet
    • 1.3.3 80mg / tablet
  • 1.4 Market Analysis by Packaging
    • 1.4.1 Overview: Global Reritinib Mesylate Tablets Consumption Value by Packaging: 2021 Versus 2025 Versus 2032
    • 1.4.2 Bottle
    • 1.4.3 Box
  • 1.5 Market Analysis by Sales Channel
    • 1.5.1 Overview: Global Reritinib Mesylate Tablets Consumption Value by Sales Channel: 2021 Versus 2025 Versus 2032
    • 1.5.2 Hospital
    • 1.5.3 Retail
    • 1.5.4 Online
  • 1.6 Market Analysis by Production Technology
    • 1.6.1 Overview: Global Reritinib Mesylate Tablets Consumption Value by Production Technology: 2021 Versus 2025 Versus 2032
    • 1.6.2 Innovator
    • 1.6.3 Generic
  • 1.7 Market Analysis by Application
    • 1.7.1 Overview: Global Reritinib Mesylate Tablets Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.7.2 EGFR-Sensitive Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    • 1.7.3 Non-Small Cell Lung Cancer With T790M Resistance Mutation After Progression on EGFR-TKI Therapy
    • 1.7.4 Second-Line Targeted Therapy for Advanced Non-Small Cell Lung Cancer
    • 1.7.5 Others
  • 1.8 Global Reritinib Mesylate Tablets Market Size & Forecast
    • 1.8.1 Global Reritinib Mesylate Tablets Consumption Value (2021 & 2025 & 2032)
    • 1.8.2 Global Reritinib Mesylate Tablets Sales Quantity (2021-2032)
    • 1.8.3 Global Reritinib Mesylate Tablets Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Nanjing Sanhome Pharmaceutical
    • 2.1.1 Nanjing Sanhome Pharmaceutical Details
    • 2.1.2 Nanjing Sanhome Pharmaceutical Major Business
    • 2.1.3 Nanjing Sanhome Pharmaceutical Reritinib Mesylate Tablets Product and Services
    • 2.1.4 Nanjing Sanhome Pharmaceutical Reritinib Mesylate Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Nanjing Sanhome Pharmaceutical Recent Developments/Updates

3 Competitive Environment: Reritinib Mesylate Tablets by Manufacturer

  • 3.1 Global Reritinib Mesylate Tablets Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Reritinib Mesylate Tablets Revenue by Manufacturer (2021-2026)
  • 3.3 Global Reritinib Mesylate Tablets Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Reritinib Mesylate Tablets by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Reritinib Mesylate Tablets Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Reritinib Mesylate Tablets Manufacturer Market Share in 2025
  • 3.5 Reritinib Mesylate Tablets Market: Overall Company Footprint Analysis
    • 3.5.1 Reritinib Mesylate Tablets Market: Region Footprint
    • 3.5.2 Reritinib Mesylate Tablets Market: Company Product Type Footprint
    • 3.5.3 Reritinib Mesylate Tablets Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Reritinib Mesylate Tablets Market Size by Region
    • 4.1.1 Global Reritinib Mesylate Tablets Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Reritinib Mesylate Tablets Consumption Value by Region (2021-2032)
    • 4.1.3 Global Reritinib Mesylate Tablets Average Price by Region (2021-2032)
  • 4.2 North America Reritinib Mesylate Tablets Consumption Value (2021-2032)
  • 4.3 Europe Reritinib Mesylate Tablets Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Reritinib Mesylate Tablets Consumption Value (2021-2032)
  • 4.5 South America Reritinib Mesylate Tablets Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Reritinib Mesylate Tablets Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Reritinib Mesylate Tablets Sales Quantity by Type (2021-2032)
  • 5.2 Global Reritinib Mesylate Tablets Consumption Value by Type (2021-2032)
  • 5.3 Global Reritinib Mesylate Tablets Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Reritinib Mesylate Tablets Sales Quantity by Application (2021-2032)
  • 6.2 Global Reritinib Mesylate Tablets Consumption Value by Application (2021-2032)
  • 6.3 Global Reritinib Mesylate Tablets Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Reritinib Mesylate Tablets Sales Quantity by Type (2021-2032)
  • 7.2 North America Reritinib Mesylate Tablets Sales Quantity by Application (2021-2032)
  • 7.3 North America Reritinib Mesylate Tablets Market Size by Country
    • 7.3.1 North America Reritinib Mesylate Tablets Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Reritinib Mesylate Tablets Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Reritinib Mesylate Tablets Sales Quantity by Type (2021-2032)
  • 8.2 Europe Reritinib Mesylate Tablets Sales Quantity by Application (2021-2032)
  • 8.3 Europe Reritinib Mesylate Tablets Market Size by Country
    • 8.3.1 Europe Reritinib Mesylate Tablets Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Reritinib Mesylate Tablets Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Reritinib Mesylate Tablets Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Reritinib Mesylate Tablets Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Reritinib Mesylate Tablets Market Size by Region
    • 9.3.1 Asia-Pacific Reritinib Mesylate Tablets Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Reritinib Mesylate Tablets Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Reritinib Mesylate Tablets Sales Quantity by Type (2021-2032)
  • 10.2 South America Reritinib Mesylate Tablets Sales Quantity by Application (2021-2032)
  • 10.3 South America Reritinib Mesylate Tablets Market Size by Country
    • 10.3.1 South America Reritinib Mesylate Tablets Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Reritinib Mesylate Tablets Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Reritinib Mesylate Tablets Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Reritinib Mesylate Tablets Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Reritinib Mesylate Tablets Market Size by Country
    • 11.3.1 Middle East & Africa Reritinib Mesylate Tablets Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Reritinib Mesylate Tablets Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Reritinib Mesylate Tablets Market Drivers
  • 12.2 Reritinib Mesylate Tablets Market Restraints
  • 12.3 Reritinib Mesylate Tablets Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Reritinib Mesylate Tablets and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Reritinib Mesylate Tablets
  • 13.3 Reritinib Mesylate Tablets Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Reritinib Mesylate Tablets Typical Distributors
  • 14.3 Reritinib Mesylate Tablets Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Reritinib Mesylate Tablets market size was valued at US$ 36.01 million in 2025 and is forecast to a readjusted size of US$ 122 million by 2032 with a CAGR of 6.7% during review period.
    Reritinib Mesylate Tablets are a highly selective oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with reritinib mesylate as the main ingredient. This drug can irreversibly inhibit EGFR sensitive mutations and T790M resistance mutations, block downstream signaling pathway transmission, inhibit tumor cell proliferation, invasion and metastasis, and exert antitumor effects. Clinically, it is mainly used for locally advanced or metastatic non-small cell lung cancer with EGFR T790M mutation-positive after progression on EGFR tyrosine kinase inhibitor therapy. Characterized by high targeting, convenient oral administration, controllable drug resistance and favorable safety profile, it is an important second-line targeted therapeutic drug for advanced non-small cell lung cancer.In 2025, global Reritinib Mesylate Tablet production reached approximately 120,000 units.
    As a domestic third-generation EGFR-TKI, Reritinib Mesylate Tablets are an important innovative product in China's lung cancer targeted therapy market. Relying on its unique molecular structure and excellent clinical efficacy, it has a differentiated advantage in the domestic competitive landscape of third-generation EGFR-TKIs. The drug is approved for non-small cell lung cancer positive for EGFR-sensitive mutations and T790M resistance mutations, with outstanding clinical efficacy and safety. It has also been included in the national medical insurance catalogue, significantly improving patients’ medication accessibility. With the implementation of medical insurance coverage for first-line indications and the upgrading of clinical guideline recommendations, its market penetration continues to rise, forming unique competitiveness among similar domestic drugs. In the future, with the advancement of combination therapy research, indication expansion, and optimization of medical insurance policies, Reritinib Mesylate Tablets will further consolidate its market position, promote a higher level of import substitution of domestic EGFR-targeted drugs, and support the high-quality development of China's precision lung cancer therapy market.
    This report is a detailed and comprehensive analysis for global Reritinib Mesylate Tablets market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Reritinib Mesylate Tablets market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Reritinib Mesylate Tablets market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Reritinib Mesylate Tablets market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Reritinib Mesylate Tablets market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Reritinib Mesylate Tablets
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Reritinib Mesylate Tablets market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Nanjing Sanhome Pharmaceutical, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Reritinib Mesylate Tablets market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    100mg / tablet
    80mg / tablet
    Market segment by Packaging
    Bottle
    Box
    Market segment by Sales Channel
    Hospital
    Retail
    Online
    Market segment by Production Technology
    Innovator
    Generic
    Market segment by Application
    EGFR-Sensitive Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Non-Small Cell Lung Cancer With T790M Resistance Mutation After Progression on EGFR-TKI Therapy
    Second-Line Targeted Therapy for Advanced Non-Small Cell Lung Cancer
    Others
    Major players covered
    Nanjing Sanhome Pharmaceutical
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Reritinib Mesylate Tablets product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Reritinib Mesylate Tablets, with price, sales quantity, revenue, and global market share of Reritinib Mesylate Tablets from 2021 to 2026.
    Chapter 3, the Reritinib Mesylate Tablets competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Reritinib Mesylate Tablets breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Reritinib Mesylate Tablets market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Reritinib Mesylate Tablets.
    Chapter 14 and 15, to describe Reritinib Mesylate Tablets sales channel, distributors, customers, research findings and conclusion.

    Buy now